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Women with epilepsy need to continue to take anti-convulsants during their pregnancies to prevent 
seizures from occurring. Since the 1980’s, it has been known that the use of valproate (an anti-
convulsant) in the first trimester of pregnancy is associated with an increased risk of spina bifida. 
Recent studies have also demonstrated increased risks of other congenital anomalies as well as a risk 
of cognitive impairment. Doctors in the EU are now advised not to prescribe valproate in pregnant 
women, in women who can become pregnant or in girls unless other treatments are ineffective or 
not tolerated. This study aimed to determine if there has been a reduction in the numbers of babies 
born with valproate syndrome in Europe from 2005 to 2014. Data from 15 European congenital 
anomaly registries, who are members of EUROCAT (A European network of population-based 
registries for the epidemiologic surveillance of congenital anomalies), identified 28 cases of 
valproate syndrome in 2.74 million births from 2005 to 2014. The prevalence of valproate syndrome 
in Europe significantly decreased from 0.22 per 10,000 births in 2005/6 to 0.03 per 10,000 births in 
2013/14. One registry, Ille de la Reunion, had the majority of cases (17). After excluding these cases 
there still remained a decreasing trend even though it no longer reached statistical significance due 
to the small number of cases.  This study emphasises the continued need for European collaboration 
in analysing rare exposures and rare anomalies.





























































Epilepsy effects about 0.5% of women of child bearing age (Wallace et al., 1998). It is necessary for 
these women to take anti-convulsants in order to prevent seizures from occurring, particularly 
during pregnancy when the seizures can be harmful to the women and also the fetus (Charlton et al., 
2015; Tomson et al., 2016). However,  first trimester exposure to anticonvulsants has been shown to 
increase the risk of congenital anomalies , particularly neural tube defects, occurring in the fetus 
(Dravet et al., 1992; Kaneko et al., 1999; Samren et al., 1997). Valproate has been identified as being 
more teratogenic than many other anti-epileptic medications, increasing the risk of spina bifida and 
other congenital anomalies including atrial septal defect, cleft palate, hypospadias, polydactyly and 
craniosynostosis (Jackson et al., 2016; Jentink et al., 2010b; Tomson et al., 2015). The term fetal 
valproate syndrome was first described in 1984 (DiLiberti et al., 1984) and includes facial 
dysmorphism, congenital anomalies and neurodevelopmental problems. Prospective studies have 
also identified an increased risk of cognitive function and neuro-developmental problems in children 
with in-utero exposure to valproate (Bromley et al., 2014; Cummings et al., 2011; Wood et al., 2015). 
Advice to pregnant women to avoid taking valproate was first considered in 1984 (DiLiberti et al., 
1984) and the warnings have been consistently strengthened with the National Institute for Clinical 
Excellence (NICE) Clinical Guidelines in 2012 recommending that women and girls of childbearing 
potential should be informed of the risks of malformation in an unborn child (2012). The 
Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency in 2018 
recommended new measures to avoid valproate exposure in pregnancy . However, if treatment with 
valproate has been providing good seizure control, women may be reluctant to change to another 
less efficient medication before or during pregnancy (Tomson et al., 2016). In addition other anti-
epileptics, such as Carbamazapine, are also teratogenic (Jentink et al., 2010a) and although the 
newer generation of anti-epileptics (such as lamotrigine and levetiracetam) appear safer there is 
limited information on  their effect on the developing fetusthem.   As many pregnancies are also 
unplanned, it may be difficult to completely prevent fetal exposure to valproate, particularly in the 
first trimester.
European surveillance of congenital anomalies (EUROCAT) is a European network of population-
based registries for the epidemiologic surveillance of congenital anomalies (EUROCAT, 
http://www.eurocat-network.eu/). It surveys all pregnancy outcomes from high-quality multiple-
source registries in Europe (Dolk, 2005).  Annual statistical monitoring for five and 10 year trends in 




























































The aim of this report is to determine if the prevalence of valproate syndrome has decreased in 15 
EUROCAT registries from 2005 to 2014.
Subjects and Methods
Data sources
Data in this study were obtained from EUROCAT registries that use multiple sources of information 
to ascertain cases in live births, late fetal deaths (20+ weeks’ gestation), and terminations of 
pregnancy for fetal anomaly at any gestation. Sources, depending on the registry, include maternity, 
neonatal, and paediatric records; fetal medicine, cytogenetic, pathology, and medical genetics 
records; specialist services including paediatric cardiology; and hospital discharge and child health 
records. The majority of registries ascertain cases diagnosed up to at least one year of life, with 
some registries having no upper age limit for registration.  All cases are coded to the International 
Classification of Diseases (ICD) version 10 with 1-digit British Paediatric Association (BPA) extension. 
Cases can have up to nine syndrome or malformation codes. All coding is completed using the 
EUROCAT guide 1.4.
Aggregate Data were extracted from the Joint Research Council ( JRC)-EUROCAT Central database in 
October 2016. The Central Database is managed by the JRC-EUROCAT Central  Registry which 
operates  the European level-coordination activities of the EUROCAT Network as part of the 
European platform on Rare Diseases  Registration.  The JRC-EUROCAT Central  Registry is located at 
the European Commission  Joint Research Centre in Ispra, Italy.
Fifteen rRegistries that had submitted data to EUROCAT for at least nine of the ten years from 2005 
to 2014 (during the study period) were included in the analysis. Cases of valproate syndrome were 
those with an ICD/BPA 10 code Q8680 (congenital malformations due to valproate), with registries 
requiring a confirmation of diagnosis by a clinical geneticist or paediatrician, rather than just a 
record of the mother having taken valproate. The present analysis was performed in the framework 
of the routine calculation of the EUROCAT prevalence tables for surveillance, using aggregated data 
and therefore the written text descriptions of the anomalies were not available.  
Statistical Analysis
The ten-year trend in prevalence was examined by fitting a multi-level Poisson regression model on 




























































number of births occurring in the area covered by the registry as the exposure. Random-effects 
models were used in order to account for potential heterogeneity across registries. A second 
multilevel Poisson model was fitted combining each two years of data and entering them as  a 
categorical variable  to provide estimates (and 95% confidence intervals (CI)) of the prevalence for 
each two year period adjusted for the registries as some registries did not have data for the whole of 
the study time period. All analyses were performed using Stata version 12.
 
Results
Table 1 shows that 28 cases with valproate syndrome were reported in 2.74 million births from 2005 
to 2014. One registry, Ille de la Reunion, had the majority of cases (17 out of 28).Figure 1 shows that 
the prevalence of valproate syndrome in Europe has significantly decreased over the past ten years 
(p<0.001) from 0.22 per 10,000 births in 2005/6 (95% CI: 0.11 to 0.39) to 0.043 per 10,000 births in 
2013/14 (95% CI:0.005 to 0.15) . After excluding the cases from Ille de la Reunion there still 
remained a decreasing trend (grey lines on figure 1) even though it no longer reached statistical 
significance due to the small number of cases.  
Registry Number of 
Pregnancies
Number of cases of 
valproate syndrome
Prevalence per 10,000 
births (95% CI)
Tuscany, Italy 299,869 0 0.00  (0.00  - 0.12)
North Netherlands 173,671 3 0.17 (0 .04 - 0 .50)
Emilia Romagna, Italy 400,208 1 0.03 (0.01 – 0.14)
Vaud, Switzerland 79,037 1 0.13 (0.00 – 0.70)
Zagreb, CroatiaϮ 66,163 0 0.00  (0.00 – 0.56)
MaltaϮ 36,820 0 0.00 (0.00 – 1.00)
South Portugal 181,903 0 0.00 (0.00 -  0.20)
Antwerp, Belgium 184,955 1 0.05 (0.00 - 0.30)
Basque Country, SpainϮ 185,352 1 0.05 (0.00 – 0.30)
Saxony Anhalt, Germany 171,877 2 0.12 (0.01 – 0.42)
Cork and Kerry, IrelandϮ 89,379 0 0.00  (0.00 – 0.41)
Wales, UK 347,032 1 0.03 (0.00 – 0.16)
Ukraine 303,935 0 0.00 (0.00 – 0.12)
Isle de la Reunion, France 145,764 17 1.17 (0.68 – 1.87)




























































Total 2,740,492 28 0.10 (0.07 – 0.15)
Ϯ : These registries only submitted data for nine years.
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Valproate Syndrome in 15 EUROCAT Registries
[Grey excludes Ille de Reunion]
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Figure 1 : Prevalence of valproate syndrome (with 95% CI and [number of cases]) in 15 EUROCAT 
registries, 2005-2014 in EUROCAT registries
Figure footnote: Grey excludes cases from Ile de la Reunion.
Discussion
There were 28 cases with valproate syndrome notified to 15 European congenital anomaly registries, 
an average of less than two cases per registry over the ten year period. This is too few within each 
registry to detect any changes in prevalence. However, combining these data across 15 registries 
enabled the clear decreasing trend to be observed. The majority of cases occurred in Ile de la 
Reunion, probably reflecting the higher prescription rates there. However a decreasing trend 
(although not significant) did remain once the cases from Ile de la Reunion were excluded. EUROCAT 
surveillance of trends across all anomaly groups is performed annually and tThis is the third year that 
the decrease in valproate syndrome has been identified in the annual EUROCAT surveillance. With 
the increasing focus on valproate syndrome in recent years (Bromley et al., 2014; Cummings et al., 
2011; Jackson et al., 2016; Jentink et al., 2010b; Tomson et al., 2015; Wood et al., 2015), it is 
reasonable to assume that under-ascertainment is not a likely explanation for the observed 
decrease. In addition an analysis of prescription databases in 7 European countries from 2004-2010 




























































(Charlton et al., 2015). A change in prescribing practice is thought to be a more likely explanation. A 
fall in prescribing valproate has also been observed in Ireland from 2008 to 2013  (Murphy et al., 
2016) and in the UK in girls from 1993 to  2006  (Ackers et al., 2009). It is important to reduce 
valproate usage in women before they become pregnant as it has been shown that switching 
medications during pregnancy carries a risk of seizures occurring (Tomson et al., 2016). In the most 
recent guideline from the EMA it is recommended not to prescribe valproate to women who can 
become pregnant or in any girls.(EMA, 2014)
A weakness limitation of the study is that the diagnosis of valproate syndrome may differ between 
registries, although EUROCAT has standard definitions for coding of congenital anomalies. A further 
limitation is that only three registries are contributing the majority of cases.  However a strength of 
this study is that it is a multi-centre collaborative study using high-quality registry data coded over 
many years in a consistent manner using the EUROCAT classification codes and inclusion criteria. The 
quality of this data enables the monitoring of trends in such rare and potentially preventable 
conditions. This study includes all registries contributing data to the surveillance of all congenital 
anomalies in October 2016. 
This study emphasises the continued need for multi-centre European collaboration in analysing 
monitoring rare congenital anomalies arising from exposure to teratogenic drugsrare exposures and 
rare anomalies. 
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